Suven Life Sciences secures Product Patent in Brazil, Eurasia
The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, said Suven Life Sciences.
Hyderabad: Suven Life Sciences Thursday said it has been granted a product patent by Brazil and Eurasia each for a new chemical entity (NCE) used in treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2023 and 2034, respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and SUVN-911.
In addition to these clinical compounds, the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.
Also Read: Suven Life Sciences secures Product Patents in Australia and Singapore
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd